Mrs Jessica B Ice, PA | |
107 Perry St, Bloomfield, KY 40008 | |
(502) 252-5081 | |
(502) 252-7211 |
Full Name | Mrs Jessica B Ice |
---|---|
Gender | Female |
Speciality | Physician Assistant |
Location | 107 Perry St, Bloomfield, Kentucky |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346261013 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | 918 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Jessica B Ice, PA Po Box 400, Bloomfield, KY 40008 Ph: (502) 252-5081 | Mrs Jessica B Ice, PA 107 Perry St, Bloomfield, KY 40008 Ph: (502) 252-5081 |
News Archive
Somanetics Corporation (Nasdaq: SMTS), a developer, manufacturer and marketer of the INVOS(R) Cerebral/Somatic Oximeter, a medical device that monitors oxygen saturation in the brain and other regions of the body, announced that it has filed a patent infringement action against CAS Medical Systems, Inc. in the United States District Court for the Eastern District of Michigan.
Mellanie True Hills knows personally the toll that atrial fibrillation (afib) takes. Just two years ago, with a sense of urgency about afib that only a survivor can possess, she designated September as Atrial Fibrillation Month.
Bionas GmbH announces the launch of its new Bionas® adcon reader for impedance-based, cellular analysis. The Bionas adcon reader technology is based on real-time monitoring of cellular impedance, thus giving real-time data about cell adhesion, membrane integrity, cellular morphology and cell proliferation for applications in toxicology, oncology, receptor signaling as well as the quality management of cells.
Air pollution – including environmental and household air pollution - has emerged as a leading risk factor for stroke worldwide, associated with about a third of the global burden of stroke in 2013, according to a new study published in The Lancet Neurology journal.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.
› Verified 2 days ago